Academic Journal
Effectiveness and Safety of Upadacitinib in the Treatment of Moderate-Severe Atopic Dermatitis: A Multicentric, Prospective, Real-World, Cohort Study
| العنوان: | Effectiveness and Safety of Upadacitinib in the Treatment of Moderate-Severe Atopic Dermatitis: A Multicentric, Prospective, Real-World, Cohort Study |
|---|---|
| المؤلفون: | Chiricozzi, Andrea, Gori, Niccolò, Narcisi, Alessandra, Balato, Anna, Gambardella, Alessio, Ortoncelli, Michela, Marzano, Angelo Valerio, Balestri, Riccardo, Palazzo, Giovanni, Pellegrino, Michele, Romanelli, Marco, Tripepi, Giovanni, Peris, Ketty, Costanzo, Antonio |
| المساهمون: | A. Chiricozzi, N. Gori, A. Narcisi, A. Balato, A. Gambardella, M. Ortoncelli, A.V. Marzano, R. Balestri, G. Palazzo, M. Pellegrino, M. Romanelli, G. Tripepi, K. Peri, A. Costanzo |
| بيانات النشر: | Springer |
| سنة النشر: | 2022 |
| المجموعة: | The University of Milan: Archivio Istituzionale della Ricerca (AIR) |
| مصطلحات موضوعية: | Settore MED/35 - Malattie Cutanee e Veneree |
| الوصف: | Background The efficacy and safety of upadacitinib in atopic dermatitis (AD) have been defined in clinical trials, but no real-world data are currently available. We aimed to assess the safety and effectiveness of upadacitinib in a real-world AD patient cohort that mostly included patients who failed the available systemic therapies, including dupilumab. Methods Prospective cohort study collecting data on upadacitinib-treated AD adult patients completing at least 16 weeks of therapy. Results Forty-three patients showed rapid and marked response to upadacitinib with significant reduction of all disease severity scores since the first follow-up visit. At week 16, Eczema Area and Severity Index (EASI) 75, EASI 90, and EASI 100 response was observed in 97.5%, 82.1%, and 69.2% of patients, respectively. EASI 90 response reflected the achievement of a clear or almost clear condition (POEM 0-2), self-evaluated by 79.5% of patients. Patients' quality of life improved as suggested by the achievement of DLQI 0/1 by 38.5% of patients at week 4, and by 76.9% at week 16. Conclusion Elevated effectiveness and favorable safety of upadacitinib were confirmed in patients unresponsive to dupilumab, who were not included in upadacitinib trials. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/pmid/35922713; info:eu-repo/semantics/altIdentifier/wos/WOS:000835596300001; volume:22; firstpage:245; lastpage:252; numberofpages:8; journal:DRUGS IN R&D; https://hdl.handle.net/2434/936302; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85135307010 |
| DOI: | 10.1007/s40268-022-00396-1 |
| الاتاحة: | https://hdl.handle.net/2434/936302 https://doi.org/10.1007/s40268-022-00396-1 |
| Rights: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.BC3E0ECD |
| قاعدة البيانات: | BASE |
| DOI: | 10.1007/s40268-022-00396-1 |
|---|